FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 31927-CIP2	SERIAL NO. 10/635,048	
	RMATION DISCLOSURE TEMENT BY APPLICANT	APPLICANT: Jallal M	lessadek	
(Use s	several sheets if necessary)	FILING DATE: August 4, 2003	GROUP: 1614	CONF. NO: 6961

#### **U.S. PATENT DOCUMENTS**

EXAM. INITIAL		DOCUMENT NUMBER							INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)	
		us	US 2002/065320						Messadek			May 30, 2002	
		4	0	6	6	7	5	6	Orr et al.			January 3, 1978	
		4	7	0	3	0	4	5	Guinot			October 27, 1987	
	-	5	8	7	6	7	8	0	Vertanen et al.			March 2, 1999	
		5	9	6	1	9	9	9	Bimczok et al.			October 5, 1999	
		6	2	3	5	3	1	1	Ullah et al.			May 22, 2001	
	<u> </u>	6	3	5	5	1	6	6	Amarasinghe et al.			March 12, 2002	
	1	6	4	7	6	0	0	6	Flashner-Barak et al.			November 5, 2002	
	<u>                                     </u>					$I^-$							
						-							

### **FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA	TION
					YES	NO
DE 19910682	September 21, 2000	Germany			X (abs- tract only)	
JP 2000-143486	May 23, 2000	Japan			X (abs- tract only)	
BE 1012546 (09900164)	December 5, 2000	Belgium			X (abs- tract only)	

# OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

	Rogers J.S., "Hypercoagulable states," W V Med J., 1993 Feb;89(2):61-3, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermTo
	Nielsen H.K., "Pathophysiology of venous thromboembolism," Semin Thromb Hemost, 1991;17 Suppl 3:250-3, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermTo
	Silver et al., "The caput medusae of hypercoagulability," J. Vasc. Surg., 2000 Feb;31(2):396-405, http://www.ncbi.nom.nih.gov/sites/entrez

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 31927-CIP2	SERIAL NO. 10/635,048	
	RMATION DISCLOSURE TEMENT BY APPLICANT	APPLICANT: Jallal M	essadek	
(Use s	several sheets if necessary)	FILING DATE: August 4, 2003	GROUP: 1614	CONF. NO: 6961

## **U.S. PATENT DOCUMENTS**

EXAM. INITIAL	DOCUMENT NUMBER				BER	INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)	

### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA	TION
					YES	NO
BE 1012712 (09900403)	February 6, 2001	Belgium			X (abs- tract only)	
BE 2003/0248	April 17, 2003	Belgium			X (abs- tract only)	
FR 77 29075 (2 403 799)	September 27, 1977	France			X (Google trans- lation only)	

# OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

Carman and Fernandez, "A Primary Care Approach to the Patient with Claudication," American Family Physician, Vol 61, No. 4, February 15, 2000, http://www.aafp.org/afp/20000215/1027.html, 8 pages
Beaufour and Beaufour, "Nouvelles associations antinévralgiques à tolérance améliorée," Brevet Spécial De Médicament, P.V. no. 927.734, No. 2.590, 1964, pp. 1-5
02/23/1996 Chinese document (pp. 91-93) with English translation entitled "Homocysteine and Vascular Disease," 5 pages
Da Silva and Sobel, "Anicoagulants: to bleed or not to bleed, that is the question," Semin Vasc. Surg. 2002 Dec;15(4):256-67, http://www.ncbi.nlm.nih.gov/siles/entrez?Db=pubmed&Cmd=ShowDetallView&TermTo
JACC Abstracts, Myocardial Ischemia and Infarction, February 2000, 1196-107, pp. 408-409
Lasch H.G., "Principles of Drug Prevention of Thrombosis," Langenbecks Arch Chir., 1986;369:451-7, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermTo
Marcel et al., From Virchow to red cells (the unended quest)., Ric Clin Lab., 1983;13 Suppl 3:71-81, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermTo

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 31927-CIP2	SERIAL NO. 10/635,048	
	RMATION DISCLOSURE TEMENT BY APPLICANT	APPLICANT: Jallal M	essadek	
(Use s	everal sheets if necessary)	FILING DATE: August 4, 2003	GROUP: 1614	CONF. NO: 6961

#### **U.S. PATENT DOCUMENTS**

EXAM. INITIAL	DOCUMEN.	T NUMBER	INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)

#### **FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA	ATION
					YES	NO
WO 02/066002	August 29, 2002	WIPO			х	
WO 98/56497	December 17, 1998	WIPO			х	
WO 99/45913	September 16, 1999	WIPO			х	

# OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

	Zöllei et al., Betaine-Palmitate Reduces Acetylsalicyclic Acid-induced Gastric Damage in Rats, Scand J.     Gastroenterol 2001 (8), pp. 811-816
	Antithrombotic effect of Betaine, Bio Ethic, January 2003, pp. 1-30
	Copy of Office Action in 09/945,391 dated November 5, 2002, 5 pages
	Copy of Office Action in 09/945,391 dated June 4, 2003, 14 pages
3,0 m	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.